|Free Dividend Report|
|Stock Splits Calendar|
|LJPC Stock Split History|
|Preferred Stock Newsletter|
|LJPC Options Chain|
|Stock Message Boards|
La Jolla Pharmaceutical (LJPC) has 1 split in our LJPC split history database. The split for LJPC took place on December 22, 2005. This was a 1 for 5 reverse split, meaning for each 5 shares of LJPC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as La Jolla Pharmaceutical conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LJPC split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into La Jolla Pharmaceutical shares, starting with a $10,000 purchase of LJPC, presented on a split-history-adjusted basis factoring in the complete LJPC split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||37.04%|
|About La Jolla Pharmaceutical|
|La Jolla Pharmaceutical is focused on the development and commercialization of therapies. GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA (eravacycline) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections. Co. owns various product candidates that are in preclinical development including: TP-6076, an IV formulation of a synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. According to our LJPC split history records, La Jolla Pharmaceutical has had 1 split.|
|LJPC Split History Table|
|12/22/2005||1 for 5|
|Healthcare Stock Splits|
|LJPC is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: LJPC shares outstanding history